China NMPA Drug Inspection - Chengdu Hexiangtian Pharmaceutical Co., Ltd. - wild chrysanthemum

The Sichuan Provincial Drug Administration (NMPA) released an announcement on December 25, 2019, outlining the findings from its 2019 drug sampling inspection program. These inspections, conducted across drug production, distribution, and usage units in various cities and prefectures throughout 2019, aimed to ensure product quality and safety within the province.The regulatory body identified 26 batches of non-compliant drugs from multiple manufacturers, including Bazhong Huikang Pharmaceutical Co., Ltd., Jilin Jibang Pharmaceutical Co., Ltd., Hebei Jinzhuan Pharmaceutical Co., Ltd., and Shangqiu Jinma Pharmaceutical Co., Ltd. Non-compliance issues primarily related to specific quality attributes, such as incorrect properties, presence of impurities (e.g., salicylic acid, auramine), inadequate identification, and deviations in the quantitative determination of active ingredients. These findings were based on criteria established in the Chinese Pharmacopoeia (2015 Edition) and relevant national supplementary inspection methods.As a result, implicated companies were directed to implement several mandatory actions. These included immediately suspending sales and use of the affected products, initiating comprehensive recalls, conducting thorough investigations into the underlying causes of the non-compliance, and executing robust rectification measures to address the identified problems.